BNT162b2 Against COVID-19-Associated Emergency Department and Urgent Care Visits Among Children 5-11 Years of Age: A Test Negative Design

被引：3

作者：

Tartof, Sara Y. ^{[1
,2
]}

Frankland, Timothy B. ^{[3
]}

Puzniak, Laura ^{[4
]}

Slezak, Jeff M. ^{[1
]}

Hong, Vennis ^{[1
]}

Takhar, Harpreet ^{[1
]}

Ogun, Oluwaseye A. ^{[1
]}

Simmons, Sarah ^{[1
]}

Xie, Fagen ^{[1
]}

Zamparo, Joann ^{[4
]}

Ackerson, Bradley K. ^{[5
]}

Jodar, Luis ^{[4
]}

McLaughlin, John M. ^{[4
]}

机构：

[1] Kaiser Permanente Southern Calif, Dept Res & Evaluat, 1000 S Los Robles,2nd Floor, Pasadena, CA 91101 USA

[2] Kaiser Permanente Bernard J Tyson Sch Med, Dept Hlth Syst Sci, Pasadena, CA USA

[3] Kaiser Permanente Hawaii Ctr Integrated Hlth Care, Honolulu, HI USA

[4] Pfizer Inc, Collegeville, PA USA

[5] Southern Calif Permanente Med Grp, Harbor City, CA USA

来源：

JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY | 2023年 / 12卷 / 03期

关键词：

BNT162b2; booster; COVID-19; delta; effectiveness; Kaiser Permanente; omicron; pediatric; real-world; SARS-CoV-2; test-negative; United States; VACCINE;

D O I：

10.1093/jpids/piad005

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

In a 1:1 matched test-negative design among 5- to 11-year-olds in the Kaiser Permanente Southern California health system (n = 3984), BNT162b2 effectiveness against the omicron-related emergency department or urgent care encounters was 60% [95%CI: 47-69] <3 months post-dose-two and 28% [8-43] after >= 3 months. A booster improved protection to 77% [53-88].

引用

页码：177 / 179

页数：3

共 35 条

[1] Real-world effectiveness of original BNT162b2 mRNA COVID-19 against symptomatic Omicron infection among children 5-11 years of age in Brazil: A prospective test-negative design study
Rodrigues, Cristina de Oliveira
Spinardi, Julia
Rosa, Regis Goulart
Falavigna, Maicon
de Souza, Emanuel Maltempi
Manfio, Joselia Larger
Souza, Ana Paula de
de Araujo, Cintia Laura Pereira
Cohen, Mirian
Barbosa, Gynara Rezende Gonzalez do Valle
Silva, Fernanda Kelly Romeiro
Sganzerla, Daniel
da Silva, Mariana Motta Dias
Ferreira, Diogo
Kunkel, Nicolas Taciano
Camargo, Nathan Iori
Sarturi, Jean Carlos
Guilhem, Marcia Cristina
de Oliveira, Jaqueline Carvalho
Lopes, Caroline Cardoso
Widmar, Fernanda
Barufi, Leticia Killes
da Silva, Gabrielle Nunes
Gradia, Daniela Fiori
Brandalize, Ana Paula Carneiro
Royer, Carla Adriane
Luiz, Rafael Messias
Baura, Valter Antonio
Abreu, Hellen
Poitevin, Carolina Gracia
Kucharski, Gabriela Almeida
Pedrotti, Fernando
Valluri, Srinivas Rao
Srivastava, Amit
Juliao, Viviane Wal
Melone, Olga Chameh
Allen, Kristen E.
Kyaw, Moe H.
Castillo, Graciela del Carmen Morales
Mclaughlin, John
IMMUNOLOGY LETTERS, 2024, 269
[2] Effectiveness of BNT162b2 and CoronaVac vaccines against omicron in children aged 5 to 11 years
Oliveira, Eduardo A.
Oliveira, Maria Christina L.
Silva, Ana Cristina Simoes e
Colosimo, Enrico A.
Mak, Robert H.
Vasconcelos, Mariana A.
Silva, Ludmila R.
Martelli, Daniella B.
Pinhati, Clara C.
Martelli-Junior, Hercilio
WORLD JOURNAL OF PEDIATRICS, 2023, 19 (10) : 949 - 960
[3] Effectiveness of BNT162b2 and CoronaVac vaccines against omicron in children aged 5 to 11 years
Eduardo A. Oliveira
Maria Christina L. Oliveira
Ana Cristina Simões e Silva
Enrico A. Colosimo
Robert H. Mak
Mariana A. Vasconcelos
Ludmila R. Silva
Daniella B. Martelli
Clara C. Pinhati
Hercílio Martelli-Júnior
World Journal of Pediatrics, 2023, 19 : 949 - 960
[4] Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 Years of Age
Tan, Sharon H. X.
Cook, Alex R.
Heng, Derrick
Ong, Benjamin
Lye, David C.
Tan, Kelvin B.
NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (06) : 525 - 532
[5] Hybrid immunity after BNT162b2 Covid-19 vaccine administration in children aged 5 to 11 years
Tsampalieros, Anne
Zemek, Roger
Barrowman, Nick
Langlois, Marc-Andre
Arnold, Corey
Mcgahern, Candice
Plint, Amy C.
Pham-Huy, Anne
Bhatt, Maala
VACCINE, 2024, 42 (20)
[6] Receipt of BNT162b2 Vaccine and COVID-19 Ambulatory Visits in US Children Younger Than 5 Years
Tartof, Sara Y.
Frankland, Timothy B.
Slezak, Jeff M.
Puzniak, Laura
Ackerson, Bradley K.
Jodar, Luis
McLaughlin, John M.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2023, 330 (13): : 1282 - 1284
[7] Cross-Sectional Survey on BNT162b2 mRNA COVID-19 Vaccine Serious Adverse Events in Children 5 to 11 Years of Age: A Monocentric Experience
Bloise, Silvia
Marcellino, Alessia
Frasacco, Beatrice
Gizzone, Pietro
Proietti Ciolli, Claudia
Martucci, Vanessa
Sanseviero, Mariateresa
Del Giudice, Emanuela
Ventriglia, Flavia
Lubrano, Riccardo
VACCINES, 2022, 10 (08)
[8] Effectiveness of BNT162b2 vaccine against symptomatic SARS-CoV-2 infection in children aged 5-11 years in Japan during Omicron variant predominate periods
Hara, Megumi
Ohta, Yuko
Fusazaki, Naoki
Hirota, Yoshio
JOURNAL OF EPIDEMIOLOGY, 2024, 34 (05) : 205 - 210
[9] Short term safety of BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine among children aged 5-11 years, a nationwide parental survey
Ben David, Shirley Shapiro
Gez, Sharon Baruch
Adler, Limor
Kovatch, Rada
Rahamim-Cohen, Daniella
Shamir-Stein, Na'ama
Shahar, Arnon
Mizrhi-Reuveni, Miri
VACCINE, 2024, 42 (05) : 1154 - 1159
[10] Safety and antibody response of the BNT162b2 SARS-CoV-2 vaccine in children aged 5-11 years with underlying diseases: A prospective observational study
Funaki, Takanori
Yamada, Masaki
Miyake, Kozue
Ueno, Saki
Myojin, Shota
Aiba, Hiroyuki
Matsui, Toshihiro
Ogimi, Chikara
Kato, Hitoshi
Miyairi, Isao
Shoji, Kensuke
JOURNAL OF INFECTION AND CHEMOTHERAPY, 2024, 30 (08) : 773 - 779

← 1 2 3 4 →